Cantor Fitzgerald Initiates Coverage on Arrowhead Research Corp(NASDAQ:ARWR). The shares have been rated Buy. The rating by Cantor Fitzgerald was issued on Aug 18, 2016.
Arrowhead Research Corp (ARWR) shares turned negative on Mondays trading session with the shares closing down -0.06 points or -0.86% at a volume of 7,67,151. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $6.95. The peak price level was also seen at $6.95 while the days lowest was $6.6. Finally the shares closed at $6.89. The 52-week high of the shares is $9.36 while the 52-week low is $3.07. According to the latest information available, the market cap of the company is $419 M.
Arrowhead Research Corp(ARWR) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q3.Company reported revenue of $39.58K. Analysts had an estimated revenue of $60.00K. Earnings per share were $-0.32. Analysts had estimated an EPS of $-0.37.
Several Insider Transactions has been reported to the SEC. On Jan 4, 2016, Kenneth Allen Myszkowski (Chief Financial Officer) sold 23,347 shares at $6.13 per share price.Also, On Jan 14, 2015, Mauro Ferrari (director) purchased 2,300 shares at $6.90 per share price.On Jan 7, 2015, David L. Lewis (Chief Scientific Officer) sold 15,000 shares at $8.01 per share price, according to the Form-4 filing with the securities and exchange commission.
Arrowhead Research Corporation is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. The Company’s products include ARC-520 ARC-521 ARC-AAT ARC-F12 ARC-HIF2 and ARC-LPA. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. ARC-AAT is an unlocked nucleobase analog-containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its Dynamic Polyconjugate platform is an RNAi delivery system that promotes high levels of target gene knockdown. ARC-F12 is an RNAi-based therapeutic designed to reduce the production of factor 12 with the goal of providing a prophylactic treatment for hereditary angioedema and thromboembolic diseases. ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A. ARC-HIF2 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 2a.